Copyright
©The Author(s) 2017.
World J Hepatol. Jan 18, 2017; 9(2): 106-113
Published online Jan 18, 2017. doi: 10.4254/wjh.v9.i2.106
Published online Jan 18, 2017. doi: 10.4254/wjh.v9.i2.106
Table 2 Change in laboratory parameters with vasopressor support as measured 24 h after vasopressor initiation
| Vasopressin (n = 21) | No Vasopressin (n = 24) | P value | |
| Platelets, k/uL, (95%CI) | -18.7 (-42.3, 4.9) | -13.6 (-31.6, 4.4) | NS |
| ALT, U/L, (95%CI) | 47.2 (-12.1, 106.6) | 206.3 (-113.3, 525.9) | NS |
| AST, U/L (95%CI) | 236.7 (74.0, 399.4) | 292.4 (-247.0, 831.8) | NS |
| Alkaline phosphatase, U/L, (95%CI) | -10.5 (-48.7, 27.8) | -19.6 (-39.5, 0.3) | NS |
| Heart rate, (95%CI) | -6.7 (-12.3, -1.0) | 0.6 (-11.8, 13.0) | NS |
| Bilirubin, mg/dL, (95%CI) | 0.45 (-0.99, 1.89) | 0.87 (-0.64, 2.38) | NS |
- Citation: Myc LA, Stine JG, Chakrapani R, Kadl A, Argo CK. Vasopressin use in critically ill cirrhosis patients with catecholamine-resistant septic shock: The CVICU cohort. World J Hepatol 2017; 9(2): 106-113
- URL: https://www.wjgnet.com/1948-5182/full/v9/i2/106.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i2.106